ArticleEuropean radiology2019
Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging.
Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.
- Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma.Alimentary pharmacology & therapeutics · 2021Pooled it
- Radiomics model based on multi-sequence MR images for predicting preoperative immunoscore in rectal cancer.La Radiologia medica · 2022Trial
- Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2022Trial
- A Computed Tomography Radiomics Approach for Assessing the T Cell-Inflamed Gene Expression Profile in Hepatocellular Carcinoma and Its Association With Immunotherapy Response.Health care science · 2026Article
- Integrating B-mode ultrasound radiomics and clinical variables to predict 26-week progression-free survival in advanced hepatocellular carcinoma under targeted immunotherapy.Abdominal radiology (New York) · 2026Article
- Multicenter peritumoral radiomics in oncology: advances, challenges, and future directions.Radiation oncology (London, England) · 2026Review
- Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging for Predicting Immunotherapy Response in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Liver cancer · 2026Review
- Preoperative prediction model of microvascular invasion in intrahepatic cholangiocarcinoma patients based on CT radiomics can assist clinical surgical decision-making: a multicenter study.European radiology · 2026Article
- METTL1-Mediated MAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A deep learning radiopathomic signature predicts recurrence risk of hepatocellular carcinoma after hepatectomy.Communications biology · 2026Article
- Emerging Role of MRI-Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review.Journal of magnetic resonance imaging : JMRI · 2026Review
- Noninvasive prediction of microvascular invasion in hepatocellular carcinoma using a fusion model of 5-mm optimal peritumoral radiomics and imaging features based on multiphasic gadoxetic acid-enhanced MRI.Frontiers in oncology · 2026Article
- Gadoxetic Acid-enhanced MRI Radiomics Features of Tumor Margins for Predicting High-Risk Solitary Hepatocellular Carcinoma Aggressiveness and Prognosis.Radiology. Imaging cancer · 2026Article
- Predicting treatment response to systemic therapy in advanced gallbladder cancer using multiphase enhanced CT images.European radiology · 2025Article
- Noninvasive Tumor Profiling: Quantitative Contrast-Enhanced MRI Markers Predict PD-L1 and CTNNB1 Status in Hepatocellular Carcinoma.Radiology · 2025Article
- MRI radiomics model for predicting tumor immune microenvironment types and efficacy of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma.BMC medical imaging · 2025Article
- A multimodal fusion system predicting survival benefits of immune checkpoint inhibitors in unresectable hepatocellular carcinoma.NPJ precision oncology · 2025Article
- MRI Imaging Biomarkers for Prognostication of Hepatocellular Carcinoma.Journal of the Korean Society of Radiology · 2025Review
- Advances in imaging techniques for tumor microenvironment evaluation in hepatocellular carcinoma.World journal of gastroenterology · 2025Review
- Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesImmunoscore evaluates the density of CD3+ and CD8+ T cells in both the tumor core and invasive margin. Pretreatment prediction of immunoscore in hepatocellular cancer (HCC) is important for precision immunotherapy. We aimed to develop a radiomics model based on gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced MRI for pretreatment prediction of immunoscore (0-2 vs. 3-4) in HCC. MATERIALS AND
methodsThe study included 207 (training cohort: n = 150; validation cohort: n = 57) HCC patients with hepatectomy who underwent preoperative Gd-EOB-DTPA-enhanced MRI. The volumes of interest enclosing hepatic lesions including intratumoral and peritumoral regions were manually delineated in the hepatobiliary phase of MRI images, from which 1044 quantitative features were extracted and analyzed. Extremely randomized tree method was used to select radiomics features for building radiomics model. Predicting performance in immunoscore was compared among three models: (1) using only intratumoral radiomics features (intratumoral radiomics model); (2) using combined intratumoral and peritumoral radiomics features (combined radiomics model); (3) using clinical data and selected combined radiomics features (combined radiomics-based clinical model).
resultsThe combined radiomics model showed a better predicting performance in immunoscore than intratumoral radiomics model (AUC, 0.904 (95% CI 0.855-0.953) vs. 0.823 (95% CI 0.747-0.899)). The combined radiomics-based clinical model showed an improvement over the combined radiomics model in predicting immunoscore (AUC, 0·926 (95% CI 0·884-0·967) vs. 0·904 (95% CI 0·855-0·953)), although differences were not statistically significant. Results were confirmed in validation cohort and calibration curves showed good agreement.
conclusionThe MRI-based combined radiomics nomogram is effective in predicting immunoscore in HCC and may help making treatment decisions. KEY POINTS: • Radiomics obtained from Gd-EOB-DTPA-enhanced MRI help predicting immunoscore in hepatocellular carcinoma. • Combined intratumoral and peritumoral radiomics are superior to intratumoral radiomics only in predicting immunoscore. • We developed a combined clinical and radiomicsnomogram to predict immunoscore in hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.